A Phase 3 interventional study of Semaglutide and Placebo in Obesity, sponsored by Novo Nordisk A/S. Active, not recruiting at 56 sites in 10 countries. Open to participants aged 6 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-10-07.
Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 143 studies testing semaglutide in Obesity — 68 open to participants now, 77 under way, 14 of them phase 3. Semaglutide · Obesity.
Among the 143 studies testing semaglutide in Obesity, this one is the 35th largest by enrollment, is one of 15 that started in 2023, is one of 42 in phase 3, reaches primary completion later than 4 of the 76 other live ones, and was the 59th registered.
11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.
Browse Obesity studies →68 of the 143 studies testing semaglutide in Obesity are open now, in 12 countries. Recruiting first, the newest first:
Vanderbilt University Medical Center · Sites in United States
Ages 18+ · Men only
McMaster University · Sites in Canada
Ages 18–60
Alain Dagher · Sites in Canada
Ages 35–55 · Healthy volunteers
Children's Hospital Medical Center, Cincinnati · Sites in United States
Ages 12–18
McGill University Health Centre/Research Institute of the McGill University Health Centre · Sites in Canada
Ages 18–65
By country, each count listing its studies:
Semaglutide: first FDA approval 2017 (OZEMPIC), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.
This study: 6 Years to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, semaglutide is the treatment under test here. Read study by study →
143 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 23 · Phase 2 24 · Phase 3 46 · Phase 4 40
First in 2014; this study’s year is marked. 15 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 212 is above the median of 67 across 9,023 interventional studies indexed under Obesity.
Median enrollment 100 across the 143 interventional studies. Of the 60 that completed or were terminated, 35 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
49 of 143 have an industry lead sponsor. The 10 most frequent:
Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
207 studies in Obesity by Novo Nordisk A/S: 48 open now, 66 under way, 26 of them phase 3. Of 138 finished, 39 (28%) have results posted.
Among the 207 studies in Obesity by Novo Nordisk A/S, this one is the 68th largest by enrollment of the 166 interventional ones that give a count, is one of 21 that started in 2023, is one of 62 in phase 3, reaches primary completion later than 2 of the 65 other live ones, and was the 100th registered.
Novo Nordisk A/S’s Obesity studies by the year they started, since 2007.
22 of the studies testing semaglutide in Obesity that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07740291Texas Tech UniversityTirzepatide Impact Assessment Study | 2026-11-23 |
| NCT07430059Vivani Medical, IncSafety, Tolerability and Pharmacokinetics of a Subcutaneous Semaglutide Implant | 2026-12 |
| NCT07225816Novo Nordisk A/SExamination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected) | 2026-12-13 |
| NCT06546384Insel Gruppe AG, University Hospital BernGLP-1 RA on Alcohol Consumption, Metabolism and Liver Parameters in Patients With Obesity and Fatty Liver Disease | 2026-12-31 |
| NCT05173714Srinvasan BeddhuSit Less, Interact and Move More (SLIMM) 2 Study | 2026-12-31 |
Add all 22 to your calendar (.ics) → With an account.
Among the 143 studies testing semaglutide in Obesity, from their registry updates:
Among Novo Nordisk A/S’s 207 in Obesity:
This tab as a report to print or save as PDF → With an account.
This study will look at how well semaglutide helps children and teenagers losing weight. This will be tested by comparing the effect on body weight in children and teenagers taking semaglutide in comparison to placebo, a "dummy" medicine. In addition to taking the medicine, the child's parent and the child will have talks with study staff about healthy food choices, how to be more physically active and what your child can do to try to lose weight. The child will either get semaglutide or a "dummy" medicine. Which treatment the child will get is decided by chance. Semaglutide is an approved medicine for type 2 diabetes and weight management in adults.
The child will get one injection once a week. The study medicine is injected with a thin needle in the stomach, thighs or upper arms. The study will last for about 2 ½ years (132 weeks).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in the age group 6 to less than (\<) 12 years will receive once weekly subcutaneous (s.c.) injection of either semaglutide or placebo matched to semaglutide in dose escalation fashion for 16 weeks (0.25 mg from weeks 0-4, 0.5 mg from weeks 5-8, 1.0 mg from weeks 9-12 and 1.7 mg from weeks 13-16) followed by 2.4 mg as maintenance dose for 88 weeks as an adjunct to a reduced-calorie diet and increased physical activity.
Drug: Semaglutide · Drug: Placebo
Participants in the age group 12 to \< 18 years will receive once weekly s.c. injection of either semaglutide or placebo matched to semaglutide in dose escalation fashion for 16 weeks (0.25 mg from weeks 0-4, 0.5 mg from weeks 5-8, 1.0 mg from weeks 9-12 and 1.7 mg from weeks 13-16) followed by 2.4 mg as maintenance dose for 88 weeks as an adjunct to a reduced-calorie diet and increased physical activity.
Drug: Semaglutide · Drug: Placebo
Semaglutide will be administered subcutaneously once weekly.
Placebo will be administered subcutaneously once-weekly.
Group Kids: Change in body mass index (BMI)
Measured in percentage (%)
Time frame: From baseline (week 0) to week 68
Group Kids: Improvement in weight category
Measured as count of participants. Weight categories based on growth charts from Center for Disease Control (CDC).gov: Normal weight= BMI less than (\<) 85th percentile, Overweight= BMI greater than or equal to (\>=) 85th - \<95th percentile, Obesity class I= BMI \>=95th - \<120% of the 95th percentile, Obesity class II= BMI \>=120% - \<140% of the 95th percentile, Obesity class III= BMI \>=140% of the 95th percentile.
Time frame: From baseline (week 0) to week 68
Group Teens: Change in BMI
Measured in %
Time frame: From week 0 to week 68
Group Kids and Group Teens: Change in BMI
Measured in %
Time frame: From week 0 to week 104
Group Teens: Improvement in weight category
Measured as count of participants. Weight categories based on growth charts from CDC.gov: Normal weight= BMI less than (\<) 85th percentile, Overweight= BMI greater than or equal to (\>=) 85th - \<95th percentile, Obesity class I= BMI \>=95th - \<120% of the 95th percentile, Obesity class II= BMI \>=120% - \<140% of the 95th percentile, Obesity class III= BMI \>=140% of the 95th percentile.
Time frame: From week 0 to week 68
Group Kids and Group Teens: Improvement in weight category
Measured as count of participants. Weight categories based on growth charts from CDC.gov: Normal weight= BMI less than (\<) 85th percentile, Overweight= BMI greater than or equal to (\>=) 85th - \<95th percentile, Obesity class I= BMI \>=95th - \<120% of the 95th percentile, Obesity class II= BMI \>=120% - \<140% of the 95th percentile, Obesity class III= BMI \>=140% of the 95th percentile.
Time frame: From week 0 to week 104
Group Kids and Group Teens: Change in body weight
Measured in percentage
Time frame: From week 0 to week 68
Group Kids and Group Teens: Change in body weight
Measured in percentage
Time frame: From week 0 to week 104
Group Kids and Group Teens: Change in body weight
Measured in kilograms (kg)
Time frame: From week 0 to week 68
Group Kids and Group Teens: Change in body weight
Measured in kilograms (kg)
Time frame: From week 0 to week 104
Group Kids and Group Teens: Change in BMI percentage of the 95th percentile
Measured in percentage points
Time frame: From week 0 to week 68
Group Kids and Group Teens: Change in BMI percentage of the 95th percentile
Measured in percentage points
Time frame: From week 0 to week 104
Group Kids and Group Teens: Change in BMI Standard deviation score (SDS)
Measured as score on a scale. BMI SDS was calculated using the following formula: Z=\[(value /M)\^L - 1\] / S\*L; where L, M and S are median (M), skewness (L) and variation coefficient (S) of children/adolescents' BMI provided for each sex and age. For each subject, a Z (SDS) score was calculated based on age and sex referring to the values L, M and S. The method is described in the WHO Multicentre Growth Reference, which also contains the values for L, M and S by age and sex. For Z (SDS) scores below -3 and above 3, the score was adjusted as described in the WHO instruction.
Time frame: From week 0 to week 68
Group Kids and Group Teens: Change in BMI SDS
Measured as score in a scale. BMI SDS was calculated using the following formula: Z=\[(value /M)\^L - 1\] / S\*L; where L, M and S are median (M), skewness (L) and variation coefficient (S) of children/adolescents' BMI provided for each sex and age. For each subject, a Z (SDS) score was calculated based on age and sex referring to the values L, M and S. The method is described in the WHO Multicentre Growth Reference, which also contains the values for L, M and S by age and sex. For Z (SDS) scores below -3 and above 3, the score was adjusted as described in the WHO instruction.
Time frame: From week 0 to week 104
Group Kids and Group Teens: Change in waist circumference
Measured in centimeters (cm)
Time frame: From week 0 to week 68
Group Kids and Group Teens: Change in waist circumference
Measured in centimeters (cm)
Time frame: From week 0 to week 104
Group Kids and Group Teens: Change in systolic blood pressure
Measured in millimeters of mercury (mmHg)
Time frame: From week 0 to week 68
Group Kids and Group Teens: Change in systolic blood pressure
Measured in millimeters of mercury (mmHg)
Time frame: From week 0 to week 104
Group Kids and Group Teens: Change in diastolic blood pressure
Measured in mmHg
Time frame: From week 0 to week 68
Group Kids and Group Teens: Change in diastolic blood pressure
Measured in mmHg
Time frame: From week 0 to week 104
Group Kids and Group Teens: Change in total cholesterol
Measured in %
Time frame: From week 0 to week 68
Group Kids and Group Teens: Change in total cholesterol
Measured in %
Time frame: From week 0 to week 104
Group Kids and Group Teens: Change in high density lipoprotein (HDL)
Measured in %
Time frame: From week 0 to week 68
Group Kids and Group Teens: Change in high density lipoprotein (HDL)
Measured in %
Time frame: From week 0 to week 104
Group Kids and Group Teens: Change in low density lipoprotein (LDL)
Measured in %
Time frame: From week 0 to week 68
Group Kids and Group Teens: Change in low density lipoprotein (LDL)
Measured in %
Time frame: From week 0 to week 104
Group Kids and Group Teens: Change in very low density lipoprotein (VLDL)
Measured in %
Time frame: From week 0 to week 68
Group Kids and Group Teens: Change in very low density lipoprotein (VLDL)
Measured in %
Time frame: From week 0 to week 104
Group Kids and Group Teens: Change in triglycerides
Measured in %
Time frame: From week 0 to week 68
Group Kids and Group Teens: Change in triglycerides
Measured in %
Time frame: From week 0 to week 104
Group Kids and Group Teens: Change in high sensitivity C-reactive protein (hs-CRP)
Measured in %
Time frame: From week 0 to week 68
Group Kids and Group Teens: Change in high sensitivity C-reactive protein (hs-CRP)
Measured in %
Time frame: From week 0 to week 104
Group Kids and Group Teens: Change in glycated haemoglobin (HbA1c)
Measured in % point
Time frame: From week 0 to week 68
Group Kids and Group Teens: Change in glycated haemoglobin (HbA1c)
Measured in % point
Time frame: From week 0 to week 104
Group Kids and Group Teens: Change in fasting plasma glucose
Measured in millimoles per liter (mmol/L)
Time frame: From week 0 to week 68
Group Kids and Group Teens: Change in fasting plasma glucose
Measured in millimoles per liter (mmol/L)
Time frame: From week 0 to week 104
Group Kids and Group Teens: Change in fasting plasma glucose
Measured in milligrams per deciliter (mg/dL)
Time frame: From week 0 to week 68
Group Kids and Group Teens: Change in fasting plasma glucose
Measured in milligrams per deciliter (mg/dL)
Time frame: From week 0 to week 104
Group Kids and Group Teens: Change in fasting insulin
Measured in %
Time frame: From week 0 to week 68
Group Kids and Group Teens: Change in fasting insulin
Measured in %
Time frame: From week 0 to week 104
Group Kids and Group Teens: Change in alanine transaminase (ALT)
Measured in milliunits per liter (mU/L)
Time frame: From week 0 to week 68
Group Kids and Group Teens: Change in alanine transaminase (ALT)
Measured in milliunits per liter (mU/L)
Time frame: From week 0 to week 104
Group Kids and Group Teens: Change in total fat mass, by Dual energy X-ray absorptiometry (DXA) relative to total body mass
Measured in % points
Time frame: From week 0 to week 68
Group Kids and Group Teens: Change in total fat mass, by Dual energy X-ray absorptiometry (DXA) relative to total body mass
Measured in % points
Time frame: From week 0 to week 104
Group Kids and Group Teens: Change in lean body mass, by DXA relative to total body mass
Measured in % points
Time frame: From week 0 to week 68
Group Kids and Group Teens: Change in lean body mass, by DXA relative to total body mass
Measured in % points
Time frame: From week 0 to week 104
Group Kids and Group Teens: Relative change in visceral fat mass by DXA
Measured in %
Time frame: From week 0 to week 68
Group Kids and Group Teens: Relative change in visceral fat mass by DXA
Measured in %
Time frame: From week 0 to week 104
Group Kids and Group Teens: Number of participants achieving greater than or equal to (>=) 5% reduction of BMI (yes/no)
Measured in count of participants
Time frame: From week 0 to week 68
Group Kids and Group Teens: Number of participants achieving greater than or equal to (>=) 5% reduction of BMI (yes/no)
Measured in count of participants
Time frame: From week 0 to week 104
Group Kids and Group Teens: Number of participants achieving greater than or equal to (>=) 10% reduction of BMI (yes/no)
Measured in count of participants
Time frame: From week 0 to week 68
Group Kids and Group Teens: Number of participants achieving greater than or equal to (>=) 10% reduction of BMI (yes/no)
Measured in count of participants
Time frame: From week 0 to week 104
Group Kids and Group Teens: Number of participants achieving greater than or equal to (>=) 15% reduction of BMI (yes/no)
Measured in count of participants
Time frame: From week 0 to week 68
Group Kids and Group Teens: Number of participants achieving greater than or equal to (>=) 15% reduction of BMI (yes/no)
Measured in count of participants
Time frame: From week 0 to week 104
Group Kids and Group Teens: Number of treatment emergent adverse events (AEs)
Measured as count of events
Time frame: From week 0 to week 68
Group Kids and Group Teens: Number of treatment emergent adverse events (AEs)
Measured as count of events
Time frame: From week 0 to week 111
Group Kids and Group Teens: Number of treatment emergent serious adverse events (SAEs)
Measured as count of events
Time frame: From week 0 to week 68
Group Kids and Group Teens: Number of treatment emergent serious adverse events (SAEs)
Measured as count of events
Time frame: From week 0 to week 111
Group Kids and Group Teens: Change in pulse
Measured as beats per minute
Time frame: From week 0 to week 68
Group Kids and Group Teens: Change in pulse
Measured as beats per minute
Time frame: From week 0 to week 104
Group Kids and Group Teens: Change in amylase
Measured as units per liter (U/L)
Time frame: From week 0 to week 68
Group Kids and Group Teens: Change in amylase
Measured as units per liter (U/L)
Time frame: From week 0 to week 104
Group Kids and Group Teens: Change in lipase
Measured as U/L
Time frame: From week 0 to week 68
Group Kids and Group Teens: Change in lipase
Measured as U/L
Time frame: From week 0 to week 104
Group Kids and Group Teens: Change in calcitonin
Measured as nanograms per liter (ng/L)
Time frame: From week 0 to week 68
Group Kids and Group Teens: Change in calcitonin
Measured as nanograms per liter (ng/L)
Time frame: From week 0 to week 104
Group Kids and Group Teens: Change in bone mineral density, by DXA
Measured as grams per square centimeter (g/cm\^2)
Time frame: From week 0 to week 68
Group Kids and Group Teens: Change in bone mineral density, by DXA
Measured as grams per square centimeter (g/cm\^2)
Time frame: From week 0 to week 104
Group Kids and Group Teens: Number of treatment emergent hypoglycaemic episodes (for T2D only)
Measured as count of episodes
Time frame: From week 0 to week 68
Group Kids and Group Teens: Number of treatment emergent hypoglycaemic episodes (for T2D only)
Measured as count of episodes
Time frame: From week 0 to week 111
Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com.
Data sharing details ↗ · novonordisk-trials.com
No publications or documents are linked to this record.
Ran from Jul 2023 to primary completion in Oct 2025, 27 months.
Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's 27 months is above that.
Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Semaglutide